Catalyst Calendar

Fri, Aug 14, 2026

1 updates

8:30 AM

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug.

Trial Results • Phase 2Results event Wed, Dec 31, 2025clene.com

Mon, Aug 10, 2026

1 updates

CLNN

8:00 AM

Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval

Survival benefit is concentrated in participants with NfL biomarker response: CNM-Au8 ® -treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controls Functional benefit concentrated in participants with NfL biomarker response: CNM-Au8-treated

Trial Results • Phase 2Biomarker analyses results Mon, Aug 10, 2026clene.com

Wed, Jul 29, 2026

1 updates

CLNN

8:30 AM

Clene to Present at The Canaccord 46th Annual Growth Conference

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases,

clene.com